Comparison
Goserelin vs. Melanotan II
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
65807-02-5
121062-08-6
Molecular weight
1269.43 g/mol
1024.18 g/mol
Half-life
4.2 h
1 h
Sequence
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Mechanism of action
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
9
of which in humans
4
5
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
2
6
Legal status
Full entries
Frequently asked questions
- What is the difference between Goserelin and Melanotan II?
- Goserelin is classified as "Research other", while Melanotan II is classified as "Research other". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Melanotan II?
- The highest available evidence level is "Human RCT" for Goserelin and "Human trial" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Melanotan II in Germany and the United States?
- Germany: Goserelin — Prescription, Melanotan II — Unapproved. United States: Goserelin — Prescription, Melanotan II — Unapproved. These are factual summaries with source and review date on the individual pages.